Acceleron to Participate in Two Healthcare Investor Conferences in March

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming healthcare investor conferences in March.

Conference Details:

Event:			Cowen and Company: 37th Annual Healthcare Conference
Date/Time:			March 6, 2017 at 2:00 p.m. EST
Location:			Boston, MA
Event:			Barclays Global Healthcare Conference
Date:			March 14, 2017
Location:			Miami, FL

A live audio webcast for the Cowen and Company Healthcare Conference will be available on the Investors page of the Company's website at www.acceleronpharma.com. A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Its pioneering research platform leverages the powerful biology behind the body’s ability to rebuild and repair its own cells and tissues. This approach to drug discovery has generated four therapeutic candidates that are currently in clinical trials. The Company’s lead therapeutic candidate, luspatercept, is being evaluated in Phase 3 studies for the treatment of the hematologic diseases, myelodysplastic syndromes (MDS) and beta-thalassemia under a global partnership with Celgene Corp. Acceleron is also advancing clinical programs in the fields of oncology and neuromuscular diseases and has a comprehensive preclinical research effort targeting fibrotic and other serious diseases.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170228005651/en/

Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior Director, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125

Source: Acceleron Pharma

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Simon Greenstone Panatier Garners Consecutive Lawyer of the Year Recognitions
• DK Homes Launches New Brand, 12 Active Communities Across the Northeast and Florida, and a Direct Land Acquisition Program
• U.S. Department of Energy Selects Nth Cycle to Enter Award Negotiations for up to $100 Million to Build New Critical Mineral Refining Facility